Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.12805PMID 26483076PMCID PMC4833148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.

  2016cited by this paper
• Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist

  2014cited by this paper
• Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study

  2014cited by this paper
• A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

  2013cited by this paper
• Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

  2013cited by this paper
• Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies

  2013cited by this paper
• National Center for Biotechnology Information (NCBI)

  2012cited by this paper
• Target site occupancy: emerging generalizations from clinical and preclinical studies.

  2009cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling and Simulation.

  2007cited by this paper
• Diagnosing Model Diagnostics

  2007cited by this paper
• Imaging of opioid receptors in the central nervous system

  2007cited by this paper
• Prediction Discrepancies for the Evaluation of Nonlinear Mixed-Effects Models

  2006cited by this paper
• Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?

  2005cited by this paper
• Prolonged Central μ-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing

  2005cited by this paper
• Effects of liver disease on the disposition of the opioid antagonist nalmefene

  1997cited by this paper
• Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.

  1997cited by this paper
• The Effect of Renal Insufficiency and Hemodialysis on the Pharmacokinetics of Nalmefene

  1996cited by this paper
• Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist

  1987cited by this paper
• Nalmefene: Intravenous safety and kinetics of a new opioid antagonist

  1986cited by this paper
• Nalmefene: radioimmunoassay for a new opioid antagonist.

  1984cited by this paper

• Clinical practice guidelines for the prevention and management of postoperative nausea and vomiting (2025 edition)

  2025cites this paper
• Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?

  2024cites this paper
• Nalmefene Hydrochloride: Potential Implications for Treating Alcohol and Opioid Use Disorder

  2024cites this paper
• Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose

  2023cites this paper
• Prophylatic use of IV nalmefene to prevent epidural opioid-induced pruritus: A multicenter, randomized clinical trial.

  2023cites this paper
• Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial

  2023cites this paper
• Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism

  2022cites this paper
• The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting-state fMRI study

  2022cites this paper
• Pharmacologic and Clinical Considerations of Nalmefene, a Long Duration Opioid Antagonist, in Opioid Overdose

  2021cites this paper
• Nalmefene, a Mu Opioid Receptor Antagonist/Kappa Opioid Receptor Partial Agonist, Potentiates Cocaine Motivation But Not Intake with Extended Access Self-Administration in Adult Male Mice.

  2021cites this paper
• Neuroendocrine effects of naltrexone versus nalmefene in humans

  2020cites this paper
• The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study.

  2019cites this paper
• The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.

  2019cites this paper
• Endogenous Opiates and Behavior: 2016.

  2018cites this paper
• Naltrexone and nalmefene attenuate cocaine place preference in male mice

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018cites this paper
• Drug‐drug interactions in the treatment for alcohol use disorders: A comprehensive review

  2018cites this paper
• Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.

  2017cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.

  2016cites this paper
• Gr upSM Opioid Receptor Antagonists and Alcohol Dependence Treatment PART

  2016cites this paper
• Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential

  2016cites this paper
• Lipophilic nalmefene prodrugs to achieve a one-month sustained release.

  2016influential citation